Related Experiment Video
Updated: Mar 19, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar
1Division of Hematology/Oncology, University of Arizona, 1515 North Campbell Ave, Tucson, AZ 85714, USA.
Abstract:
The World Health Organization defines a biosimilar as "a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product." Biosimilars are biologic medical products that are very distinct from small-molecule generics, as their active substance is a biological agent derived from a living organism. Approval processes are highly regulated, with guidance issued by the European Medicines Agency and US Food and Drug Administration. Approval requires a comparability exercise consisting of extensive analytical and preclinical in vitro and in vivo studies, and confirmatory clinical studies. Extrapolation of biosimilars from their original indication to another is a feasible but highly stringent process reliant on rigorous scientific justification. This review focuses on the processes involved in gaining biosimilar approval and extrapolation and details the comparability exercise undertaken in the European Union between originator erythropoietin-stimulating agent, Eprex(®), and biosimilar, Retacrit™.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence: Overview
Bioequivalence studies: Biowaivers
Bioequivalence Data: Statistical Interpretation
Pharmaceutical Equivalents

